At a glance
What is it—and why does it matter?
Liraglutide is a glucagon-like peptide 1 analogue. Liraglutide activates the GLP-1 receptor, which signals through Gs to activate adenylyl cyclase. In a double-blind trial, people with type 2 diabetes and high cardiovascular risk were assigned to liraglutide or placebo. Animal studies suggest fetal risk from liraglutide exposure in pregnancy; use in pregnancy only if benefit outweighs risk.
Each sentence above is copied from a published claim presentation. The links open its evidence record.
Think of Liraglutide as the active molecule. The named products below are specific ways that molecule is formulated, approved, and used. [1]Regulatory labelVictoza prescribing informationDailyMed label for liraglutide marketed as Victoza.
Simple guide
Liraglutide, in plain English
The main points from the published research. Each one links to the source it comes from.
What it is
A lab-made peptide medicine that copies a natural body signal involved in blood sugar and appetite.
Liraglutide is a GLP-1 receptor agonist in this study.
Source for this finding
“Acute vascular responses to the GLP-1R agonist liraglutide were quantified”
A GLP-1 receptor agonist enhances islet microvascular flow through nitric oxide-dependent mechanisms in a diabetic mouse model: investigation using intravital two-photon imaging.
- Status
- FDA-approved ingredient
- Approved use
- Victoza and Saxenda are separate products with different target doses and indications.
What the research looks like
Research on Liraglutide is a mix of studies in people and animal or lab studies.
- 67 People 20%
- 60 Animals or lab 18%
- 210 Other or unclear 62%
Counts show where findings come from, not how strong they are. Animal and lab findings are counted together because study types have not been labelled for this profile yet.
What studies in people found
In a double-blind trial, people with type 2 diabetes and high cardiovascular risk were assigned to liraglutide or placebo.
Source for this finding
“Methods In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo.”
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.In this review, liraglutide was one of the drugs associated with the greatest weight reduction in antipsychotic-treated people with schizophrenia spectrum disorders.
Source for this finding
“Semaglutide, liraglutide, topiramate, metformin, and exenatide were associated with the greatest reductions in body weight and were supported by the highest-certainty evidence, providing guidance for clinicians managing antipsychotic-associated weight gain.”
Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.The primary kidney outcome combined new diagnosis codes for CKD stages 3-4 and kidney failure (including CKD stage 5 and kidney replacement therapy).
Source for this finding
“A primary kidney composite outcome inclusive of incident diagnosis codes for CKD stages 3-4 and kidney failure (inclusive of CKD stage 5 and kidney replacement therapy).”
Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes.In this study, people with BMI ≥ 25 kg/m² using liraglutide for weight control were compared with people using MCLOW over 12 months.
Source for this finding
“From January 1, 2013, to December 31, 2018, subjects from the multi-institutional Chang Gung Research Database (CGRD) with a BMI ≥ 25 kg/m² received a fixed combination of Ma-Xing-Gan-Shi-Tang andCoptis chinensisFranch, namely Ma-Xing-Gan-Shi-Tang and Coptis chinensis Franch LOwering Weight formula (MCLOW), were compared with those using liraglutide for weight control for a 12-month follow-up course with overlap weighting for baseline inequality.”
pubmed-42500463In a randomized study in overweight or obese people with type 2 diabetes, 7-day treatment with IDegLira plus insulin aspart was compared with insulin glargine plus insulin aspart.
Source for this finding
“In this randomized study, severely hyperglycemic overweight or obese patients with T2DM received 7-day intensive therapy with either IDegLira plus insulin aspart or insulin glargine plus insulin aspart.”
Comparative analysis of IDegLira versus insulin glargine in short-term intensive therapy for overweight or obese patients with type 2 diabetes mellitus.
What animal and lab studies suggest
Not proven in people. Results in animals or cells often do not hold up in humans.
In solution-state analyses, diffusion behavior was comparable between the test products and the RLD.
Source for this finding
“Solution-state analyses showed comparable diffusion behavior”
An Orthogonal Framework for Higher-Order Structural and In Vitro Functional Comparability of Chemically Synthesized Liraglutide Relative to an rDNA-Origin Reference Product.A head-to-head comparability study compared chemically synthesized liraglutide with a recombinant reference listed drug (RLD).
Source for this finding
“A head-to-head comparability study was performed between a chemically synthesized liraglutide product and its recombinant reference listed drug (RLD).”
An Orthogonal Framework for Higher-Order Structural and In Vitro Functional Comparability of Chemically Synthesized Liraglutide Relative to an rDNA-Origin Reference Product.In rats, liraglutide plus deferoxamine worked better than either treatment alone on heart function, iron measures, antioxidant defenses, and heart tissue structure.
Source for this finding
“however, combined therapy produced superior restoration of ventricular function, normalization of iron parameters, enhancement of antioxidant defenses, and preservation of myocardial architecture.”
Synergistic cardioprotection by liraglutide and deferoxamine against doxorubicin-induced cardiotoxicity via modulation of ACSL-4/Nrf-2/GPX-4 signaling.
Safety
Labels warn about thyroid C-cell tumors observed in rodents; human relevance is unknown.
Serious risks listed on the product label:
- Pancreatitis
- Gallbladder disease
- Hypoglycemia with selected therapies
Do not use liraglutide injection if there is a personal/family history of MTC or if the patient has MEN 2.
Source for this finding
“Liraglutide injection is contraindicated in:Patients with a personal or family history of medullary thyroid carcinoma (MTC) or patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
These highlights do not include all the information needed to useLIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval: 2010“Liraglutide injection is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).”
These highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval: 2010Do not use liraglutide injection if you or your family have had MTC, or if you have MEN 2.
Source for this finding
“Liraglutide injection is contraindicated in:Patients with a personal or family history of medullary thyroid carcinoma (MTC) or patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
These highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval: 2010VICTOZA should not be used in people with a personal or family history of MTC or with MEN 2.
Source for this finding
“VICTOZA is contraindicated in patients with a:•personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
These highlights do not include all the information needed to use VICTOZA®safely and effectively. See full prescribing information for VICTOZA.VICTOZA (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010
How it's used
These describe specific products as labelled or studied. They are not dosing instructions.
Inject liraglutide under the skin once daily, any time of day, with or without meals.
Source for this finding
“Inject liraglutide injection subcutaneously once daily at any time of day, without regard to the timing of meals.”
These highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval: 2010Victoza is a 6 mg/ml pre-filled pen injection taken once daily under the skin in the abdomen, thigh, or upper arm.
Source for this finding
“Victoza is a solution for injection available in pre?filled pens (6 mg/ml). Victoza is given by the patient once a day by injection under the skin in the abdomen, thigh or upper arm.”
Victoza | European Medicines Agency (EMA)
What we don't know
This profile does not list specific open questions yet.
A missing finding does not mean something is safe or effective.
Identity + structure
A molecule, not a product name.
| Preferred name | Liraglutide | Ingredient |
|---|---|---|
| Pharmacologic class | GLP-1 receptor agonist | Profile record |
| Peptide structure | 31 amino acids | Profile record |
| Also indexed as | liraglutide · GLP-1 analog | Search aliases |
Mechanism + clinical pharmacology
What it does in the body.
Activates GLP-1 receptors to increase glucose-dependent insulin secretion, decrease glucagon, reduce appetite, and delay gastric emptying. [1]Regulatory labelVictoza prescribing informationDailyMed label for liraglutide marketed as Victoza.
See all 376 findings and sourcesEvery finding, grouped by topic, with its exact source passages
Evidence ledger
What the evidence says.
These are evidence statements, not individualized medical instructions. Product, dose, population, and study context remain attached to each source.
Study findings
What studies observed in defined populations, comparators, and time periods.
Liraglutide lowers glucagon release in a glucose-dependent way.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
GLP-1RA use was linked to lower risk of posterior subcapsular cataracts than other weight-loss drugs in sensitivity analyses.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study checked for laryngeal symptoms within 1, 3, and 6 months after starting GLP-1 receptor agonists (which included liraglutide).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The main composite outcome happened less often with liraglutide than with placebo (hazard ratio 0.87; 95% CI, 0.78 to 0.97).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In the LEADER trial, liraglutide reduced MACE compared with placebo (hazard ratio 0.87 [0.78; 0.97]).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In adults having cardiac surgery, perioperative subcutaneous liraglutide did not change 30-day mortality versus placebo or insulin-based usual care.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In T2DM mice, liraglutide plus dapagliflozin improved metabolism more than either drug alone, including less weight loss and better glucose tolerance.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In 28 normoglycaemic, non-obese rabbits, liraglutide reduced atherosclerosis progression versus controls on IVUS Δ percent atheroma volume.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 18 months, % total weight loss was higher with liraglutide groups than controls (P < 0.05).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
People who started Saxenda had 48.7% mean yearly adherence (PDC).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1RA use (liraglutide or semaglutide) was linked to lower 5-year dry eye syndrome risk than other weight-loss drugs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In ESRD, liraglutide was associated with a pooled body-weight change of -2.24 kg after 3 months (95% CI: -7.73, 3.26; I2= 0.0%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In FFA-injured HepG2 cells, liraglutide reduced lipid buildup, oxidative stress, and iron overload.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide injection is used with diet and exercise to improve blood sugar control in adults and children age 10 years and older with type 2 diabetes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide injection is used with diet and exercise to improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Islets from RIIβ-knockout mice secreted less insulin after liraglutide stimulation.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In human umbilical vein endothelial cells, tirzepatide and liraglutide produced similar nitric oxide levels when tested at the same molar concentration.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1RA use (liraglutide or semaglutide) was linked to lower 5-year ocular hypertension risk than other weight-loss drugs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
By week 56, average weight loss was 8.4±7.3 kg with liraglutide vs 2.8±6.5 kg with placebo (difference -5.6 kg; 95% CI -6.0 to -5.1; P<0.001; LOCF).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Islets from RIIβ-knockout mice secreted less insulin after liraglutide stimulation.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study tested liraglutide for cardioprotection in a rat doxorubicin heart-toxicity model.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In T2DM mice, liraglutide plus dapagliflozin better preserved the aorta and reduced endothelial cell death than either drug alone.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In islets from donors with glucose intolerance, liraglutide 25 nmol/l increased glucose-stimulated insulin secretion (n=7, p=0.021).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide injection is used (with diet and activity) for long-term weight management in adults and in patients aged 12 years and older who weigh more than 60 kg and have obesity.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In chow-fed mice, liraglutide did not stimulate insulin in GLP-1RTanycyteKD mice (responses were abolished).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 100% coverage (broad criterion), the annual liraglutide budget was S/142.95 billion.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
IDegLira plus insulin aspart gave better short-term glycemic control than insulin glargine plus insulin aspart in overweight or obese people with type 2 diabetes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In adults having cardiac surgery, perioperative subcutaneous liraglutide did not change the overall rate of any postoperative complication versus control.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across three 56-week placebo-controlled trials, liraglutide injection led to statistically significant weight reduction versus placebo at 56 weeks.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In vitro, the nanomotor increased insulin secretion by 1.81-fold versus passive nanoparticles.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1RA use (liraglutide or semaglutide) was linked to lower 5-year POAG risk than other weight-loss drugs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across 3 retrospective cohort studies, GLP-1 RA exposure (including liraglutide) before conception or in the first trimester was not significantly linked to HDP (OR 0.91; CI 0.57-1.47).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide shifted the gut bacterial community during treatment, and it mostly returned to baseline after 7 days of washout.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In T2DM mice, liraglutide plus dapagliflozin lowered CK-MB and LDH more than either drug alone.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Among 27,443 body contouring patients, liraglutide use increased over time (τ = .78, P = .002).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Direct randomized sleep-apnea evidence for incretin therapy is mostly from liraglutide (and tirzepatide).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide lowers body weight by reducing calorie intake and does not raise 24-hour energy expenditure.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide injection is used to lower the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide slows (delays) gastric emptying.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
RIIβ-knockout mice had worse glucose tolerance and weaker insulin secretion when given liraglutide.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide lowers body weight by reducing calorie intake.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In these mice, liraglutide caused significant weight loss by Day 4; it lasted during treatment and partly reversed after stopping.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the LEADER trial, VICTOZA reduced MACE versus placebo (hazard ratio 0.87 [0.78, 0.97]).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In human donor islets, liraglutide at 25 nmol/l increased glucose-stimulated insulin secretion in glucose intolerance donors (n=7, p=0.021) but not in normoglycaemic donors (n=7).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In diabetic mice, acute liraglutide increased peri-islet vascular volume fraction and erythrocyte velocity.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Twelve ASVs tied to Romboutsia, Faecalicatena, and Oscillibacter decreased during liraglutide treatment.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this cohort, Saxenda had lower persistence and adherence than Zepbound and Wegovy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The findings say liraglutide quickly and reversibly changes the gut microbiome in a diet-dependent way, increasing lactic acid–producing bacteria and decreasing fermentative taxa.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1RA use was linked to less use of dry eye-related medication than other weight-loss drugs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In type 2 diabetic mice, the nanomotor lowered OGTT glucose AUC to 52.25% of diabetic controls.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a time-to-event analysis, the first occurrence of cardiovascular death, nonfatal heart attack, or nonfatal stroke was lower with liraglutide than placebo in type 2 diabetes.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
GLP-1RA use was linked to lower risk of nuclear cataract than other weight-loss drugs in sensitivity analyses.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 1 year, persistence on Saxenda was 34.2% and was significantly lower than Zepbound and Wegovy (log-rank P < .001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
VICTOZA is used with diet and exercise to improve blood sugar control in adults and in children aged 10 years and older with type 2 diabetes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In HepG2 cells, free fatty acids increased lipid accumulation, TG, MDA, and iron, and decreased SOD activity and GSH versus control (all p<0.05).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In NRK-52E cells under high salt, ACE1 and AGTR1 went up and NHE3 phosphorylation went down; liraglutide reversed these changes.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In 28 normoglycaemic, non-obese rabbits, liraglutide lowered NIRF-OCT plaque cathepsin activity versus controls.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Death from any cause was lower with liraglutide than with placebo (hazard ratio 0.85; 95% CI, 0.74 to 0.97).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The review examines animal and human studies on liraglutide’s effects on food intake and body weight.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After 56 weeks, people on liraglutide lost more weight than placebo (difference -5.6 kg).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In type 2 diabetic mice, the nanomotor alleviated insulin resistance.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1RA use was linked to lower risk of cortical cataract than other weight-loss drugs in sensitivity analyses.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Cardiovascular death occurred less often with liraglutide than with placebo (hazard ratio 0.78; 95% CI, 0.66 to 0.93).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In antipsychotic-treated people with schizophrenia spectrum disorders, liraglutide was associated with more weight loss than placebo (mean difference -5.43 kg; 95% CI, -8.54 to -2.33; 2 trials; moderate certainty).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1RA use was linked to lower risk of retinal haemorrhage or edema than other weight-loss drugs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In donor islets, GLP-1R mRNA was lower with higher HbA1c in type 2 diabetes (p=0.015; normoglycaemic n=48 vs type 2 diabetes n=10).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In six main studies (4,289 people), Victoza’s main effectiveness measure was HbA1c reduction after six months or one year.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In older non-diabetic adults with overweight/obesity, GLP-1RA use (liraglutide or semaglutide) was linked to a lower 5-year cataract risk than other weight-loss drugs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1RA use (liraglutide or semaglutide) was linked to lower 5-year AMD risk than other weight-loss drugs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
PCPs who had prescribed liraglutide before were more likely to feel comfortable helping patients manage weight after GLP-1 drug coverage was lost (aOR 2.34, 95% CI 1.05-5.24).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this study, GLP-1 receptor agonist use was not significantly linked to a higher risk of NAION than SGLT-2 inhibitors or DPP-4 inhibitors (HR: 1.87; 95%CI: 0.85-4.12).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide lowers body weight by reducing calorie intake.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide lowers body weight by reducing calorie intake and does not raise 24-hour energy expenditure.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In male Wistar rats treated with doxorubicin, liraglutide pretreatment significantly reduced multiple measured signs of doxorubicin-related cardiac injury and associated oxidative/ferroptosis changes.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Compared with Wegovy, Saxenda had a higher hazard of discontinuation (HR: 1.26, 95% CI: 1.01-1.16).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In salt-sensitive hypertensive rats, liraglutide lowered tail-cuff systolic blood pressure versus control (167.00±9.98 mmHg vs. 182.00±6.26 mmHg; P<0.05).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide injection is used with diet and exercise for long-term weight management in adults and in ages 12+ with obesity who weigh more than 60 kg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In glucose-intolerant donor islets, liraglutide 25 nmol/l increased glucose-stimulated insulin secretion (n=7, p=0.021).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Nine ASVs linked to Lactobacillus gasseri, L. paragasseri, L. johnsonii, and Leptogranulimonas caecicola rose during treatment and fell after washout.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In vitro, the nanomotor increased intestinal epithelial cell uptake by 4.17-fold versus passive nanoparticles.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide injection is used with diet and more physical activity to reduce excess body weight and help keep weight off long term in certain adults and in some children age 12+.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Comparative evidence
How the studied intervention compared with another intervention, comparator, or threshold.
Liraglutide STADA contains the same active substance as Victoza, but it is chemically synthesised while the reference product’s active substance is of biological origin.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In adults (monotherapy), Victoza lowered HbA1c by 0.8 points (1.2 mg) or 1.1 points (1.8 mg) versus 0.5 points with glimepiride.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In a double-blind trial, people with type 2 diabetes and high cardiovascular risk were assigned to liraglutide or placebo.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide Stada is a hybrid medicine of Victoza (liraglutide), authorised in the EU since 30 June 2009.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this review, liraglutide was one of the drugs associated with the greatest weight reduction in antipsychotic-treated people with schizophrenia spectrum disorders.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The primary kidney outcome combined new diagnosis codes for CKD stages 3-4 and kidney failure (including CKD stage 5 and kidney replacement therapy).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In solution-state analyses, diffusion behavior was comparable between the test products and the RLD.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this study, people with BMI ≥ 25 kg/m² using liraglutide for weight control were compared with people using MCLOW over 12 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a randomized study in overweight or obese people with type 2 diabetes, 7-day treatment with IDegLira plus insulin aspart was compared with insulin glargine plus insulin aspart.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide STADA has the same active substance as Victoza, but is chemically synthesised rather than of biological origin.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
People taking liraglutide or semaglutide were matched 1:1 to people taking other weight-loss drugs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The secondary kidney outcome added death from any cause to the primary kidney composite outcome.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In these Parkinson’s disease trials, GLP-1 receptor agonists (including liraglutide) were compared with placebo.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A head-to-head comparability study compared chemically synthesized liraglutide with a recombinant reference listed drug (RLD).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In rats, liraglutide plus deferoxamine worked better than either treatment alone on heart function, iron measures, antioxidant defenses, and heart tissue structure.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this cohort, liraglutide contributed more GLP-1 receptor agonist follow-up time (72.9%) than semaglutide, exenatide, dulaglutide, or lixisenatide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study found no difference in the primary kidney outcome among dulaglutide, exenatide, liraglutide, and semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In 134 adolescents and children aged 10 years and up, HbA1c fell by 0.64 points with Victoza and rose by 0.42 points with placebo.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This review compared once-weekly semaglutide with several injectable therapies, including liraglutide, in adults with type 2 diabetes not controlled on oral drugs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The analysis compared GLP-1 receptor agonists (including liraglutide) with other glucose-lowering medicines for reports of depressed mood and suicidal thoughts.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across randomized trials in a network meta-analysis, liraglutide was linked to a lean body mass decrease of -1.54 kg (95% CI: -2.55 to -0.52).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Mechanism
Source-backed statements about targets, pathways, and biological response.
In diabetic mice, L-NAME completely abolished liraglutide’s acute vascular responses.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Researchers developed an in vitro AVP luciferase test to measure how synaptic protein phosphorylation affects AVP secretion.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide increases insulin release from the pancreas in response to food, helping control blood glucose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide was tested for effects on oxidative stress and wound healing in human skin cells in diabetes-like lab conditions.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide activates the GLP-1 receptor, which signals via Gs to adenylyl cyclase.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The study used GLP-1RTanycyteKD and iBot mice to separate central from peripheral pathways.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Eighty five % of liraglutide’s protein effects stayed after adjusting for weight, suggesting they are mostly weight-independent.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide mimics incretin hormones and increases insulin release after food, helping control blood sugar.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide helps trigger insulin release when blood glucose is high.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Acute activation of GLP-1R rapidly increases NO-dependent islet microvascular flow under diabetic conditions.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is a long-acting GLP-1 receptor agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide activated human GLP-1 receptor in HEK293 cells with EC50 0.0093 nM for cAMP after 20 mins.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The analysis computed PRR, ROR, 95% confidence intervals, and Fisher exact tests.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is a GLP-1 receptor agonist.
2 cited sources · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records. 2 publication group(s) lack a resolved study identity.
Liraglutide works by activating the GLP-1 receptor.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide slows stomach emptying.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Biliary adverse events have been reported with GLP-1 receptor agonists.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In HepG2 cells exposed to free fatty acids, liraglutide partially reversed ferroptosis-related changes (lower MDA and iron, lower TFR1, higher NRF2 and GPX4), with all comparisons p<0.05.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study performed subgroup and sensitivity analyses.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
It is unclear how biliary adverse event reporting differs within the GLP-1 receptor agonist class.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide forms dynamic oligomers that are not intrinsically stable when agitated.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 receptor agonists can have cardiometabolic benefits beyond weight loss, but how they change proteins across the body is not fully known.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide increases cAMP and triggers insulin release when blood glucose is high.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The study used multiple analytical methods (including NMR and in vitro functional tests) to assess structure, assembly, aggregation, and biological activity.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study examined whether liraglutide’s mechanism changes across stages of metabolic dysfunction to explain variable patient responses.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study measured short-term protein changes after liraglutide and compared them with known semaglutide protein signatures.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
GLP-1 receptor mRNA was measured in 112 donor islet samples grouped by HbA1c.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In type 2 diabetes donor islets, higher HbA1c was associated with lower GLP-1 receptor mRNA (p=0.015; n=48 vs n=10).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Glucagon-like peptide-1 receptor agonists lower blood glucose only when glucose is high.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide’s effects in FFA-injured HepG2 cells were linked to changes in ferroptosis-related genes.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study tested whether liraglutide could reduce ferroptosis in an in vitro MASLD model.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide activates the GLP-1 receptor.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Part of liraglutide’s blood-glucose-lowering effect comes from delaying gastric emptying.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide activates GLP-1 receptors and increases cAMP, which leads to insulin release when glucose is high.
4 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
5 cited passages across 4 source records.
Liraglutide activates the GLP-1 receptor, which signals through Gs to activate adenylyl cyclase.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide was one of the GLP-1 drugs compared using a combined “Skin and Injection-Site Reactions” category.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In mice after a 27-week high-fat diet, liraglutide still worked on islets ex vivo but no longer enhanced insulin in vivo, and glucose lowering involved reduced hepatic gluconeogenesis and increased peripheral glucose uptake.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is a long-acting GLP-1 agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
NMR showed liraglutide interacts strongly and specifically with PS80, but not with PX188.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A FAERS disproportionality analysis compared biliary outcomes across several GLP-1RAs including liraglutide, with semaglutide as the reference.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study measured key signaling pathways using Western blot and qPCR.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
High-pressure NMR is presented as a main tool in an integrated strategy to study peptide-therapeutic aggregation in water-based formulations.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In HepG2 cells, free fatty acids raised TFR1 and lowered SLC7A11, NRF2, and GPX4 versus control (p<0.05).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Pharmacokinetics
How the studied compound is absorbed, distributed, metabolized, and cleared.
After a subcutaneous dose, liraglutide peaks at 8 to 12 hours.
5 cited sources · 4 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
6 cited passages across 5 source records.
Liraglutide’s elimination half-life after subcutaneous dosing is about 13 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The nanomotors were put into sodium alginate hydrogel microspheres to protect liraglutide (Lira) from gastric-acid degradation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After a subcutaneous dose, liraglutide reaches peak concentration at 11 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After a subcutaneous dose, liraglutide has a plasma half-life of 13 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After a subcutaneous dose, liraglutide reaches peak levels in about 8 to 12 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After a subcutaneous dose, liraglutide peaks at 8-12 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After a subcutaneous dose, liraglutide reaches maximum concentration in 8 to 12 hours.
2 cited sources · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 2 source records.
After a subcutaneous dose, liraglutide reaches its maximum concentration in about 8 to 12 hours.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
After a subcutaneous dose, liraglutide reaches its maximum concentration at 8-12 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After a subcutaneous dose, liraglutide reaches its maximum concentration at 11 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After a subcutaneous dose, liraglutide reaches its maximum concentration at 11 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After a subcutaneous injection, liraglutide has a plasma half-life of 13 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In lactating rats, liraglutide was found unchanged in milk at about 50% of the mother’s plasma level.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this cohort, liraglutide made up 72.9% of GLP-1 receptor agonist follow-up time.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After a subcutaneous dose, liraglutide’s plasma half-life is 13 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Safety findings
Observed or labeled risks, adverse effects, and safety signals.
Routine calcitonin blood tests or thyroid ultrasound may not reliably detect MTC early in people treated with liraglutide injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In adults, using Victoza with a sulfonylurea or insulin may increase the risk of low blood sugar, including severe low blood sugar.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rats and mice, liraglutide caused thyroid C-cell tumors; whether SAXENDA causes these tumors in humans is unknown.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In five adult trials (26 weeks or longer), 9% (102/1,104) of VICTOZA-treated patients developed anti-liraglutide antibodies.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Severe gastrointestinal side effects were more common with VICTOZA (1.2 mg 4.4%, 1.8 mg 4.2%) than with placebo (1.1%) in clinical trials.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rats and mice, liraglutide caused thyroid C-cell tumors in a dose- and duration-dependent way; it is unknown if VICTOZA causes these tumors in humans.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Pancreatitis (including severe and sometimes fatal forms) has been observed in people treated with GLP-1 receptor agonists, including liraglutide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Common side effects (may affect more than 1 in 10 people) include nausea, vomiting, diarrhoea, and constipation.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Animal studies suggest fetal risk from liraglutide exposure in pregnancy; use in pregnancy only if benefit outweighs risk.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rats and mice, liraglutide caused thyroid C-cell tumors in a way that depended on dose and how long treatment lasted; whether this happens in humans is unknown.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rats and mice, liraglutide caused thyroid C-cell tumors in a way that depended on dose and how long treatment lasted.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
It is not known whether liraglutide injection causes thyroid C-cell tumors (including MTC) in people.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In pregnancy, use liraglutide only if the benefit outweighs fetal risk; weight loss is not beneficial in pregnancy and may harm the fetus.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not share a liraglutide injection pen with anyone else, even if you change the needle, because it can spread blood-borne infections.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rats and mice, liraglutide caused thyroid C-cell tumors in a dose- and duration-dependent way; it is unknown if this applies to humans.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In the LEADER trial, liraglutide 1.8 mg did not show an increased risk of MACE versus placebo over a median 3.5 years.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rats and mice, liraglutide caused thyroid C-cell tumors; it is not known if it causes these tumors in people.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not share a Victoza pen, even with a new needle, because it can spread blood-borne infections.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Contraindications
Circumstances in which a specific product label says it should not be used.
Do not use liraglutide injection if there is a personal/family history of MTC or if the patient has MEN 2.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Do not use liraglutide injection if you have a personal or family history of MTC or if you have MEN 2.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Do not use SAXENDA if there is a personal or family history of MTC or if the patient has MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use liraglutide injection if a patient has (or has a family history of) MTC, or has MEN 2.
4 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 4 source records.
Do not use liraglutide injection if you or your family have had MTC, or if you have MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use liraglutide injection if you or your family have had MTC, or if you have MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use SAXENDA in people with a personal or family history of MTC or with MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use liraglutide if there is a personal or family history of MTC or if the patient has MEN 2.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Do not use liraglutide in people with a personal or family history of MTC or with MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use liraglutide if you or your family have had MTC, or if you have MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use liraglutide if you or your family have had MTC, or if you have MEN 2.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Do not use liraglutide in people with a personal or family history of MTC or with MEN 2.
2 cited sources · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Do not use liraglutide injection if you have (or have a family history of) MTC, or if you have MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use liraglutide if you have a personal/family history of MTC or have MEN 2.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Do not use VICTOZA if there is a personal or family history of MTC, or if the patient has MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use liraglutide injection if you or your family have had MTC, or if you have MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
VICTOZA should not be used in people with a personal or family history of MTC or with MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use VICTOZA if you have a personal or family history of MTC or if you have MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use liraglutide if you or your family have had MTC, if you have MEN 2, or if you have had a serious allergic reaction to liraglutide or its ingredients.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use SAXENDA if you or your family have had MTC, or if you have MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Interactions
Source-backed product and drug interaction statements.
Do not use liraglutide injection together with other products that contain liraglutide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use liraglutide injection together with other liraglutide products or other GLP-1 receptor agonists.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide injection delays stomach emptying and may affect how oral medicines are absorbed.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use Liraglutide Injection together with other products that contain liraglutide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Using SAXENDA together with other liraglutide products or other GLP-1 receptor agonists is not recommended.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use liraglutide injection together with other liraglutide products or other GLP-1 receptor agonists.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use liraglutide injection together with other liraglutide products or other GLP-1 receptor agonists.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not combine liraglutide injection with other liraglutide products or other GLP-1 receptor agonists.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If using insulin too, inject liraglutide separately and do not mix them.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If Victoza is added to a sulphonylurea or insulin, the doctor may consider lowering the other drug’s dose to reduce hypoglycaemia risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide injection stimulates insulin release when blood glucose is elevated.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use Liraglutide Injection together with other medicines that also contain liraglutide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use liraglutide injection with other liraglutide products or other GLP-1 receptor agonists.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If Victoza is added to a sulphonylurea or insulin, the other medicine’s dose may need to be lowered to reduce hypoglycaemia risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Using liraglutide with a sulfonylurea or insulin can increase the risk of hypoglycemia, including severe hypoglycemia.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not combine liraglutide injection with other liraglutide products or other GLP-1 receptor agonists.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Regulatory status
Product-, indication-, and jurisdiction-specific regulatory records.
Do not use Liraglutide Injection together with other medicines that contain liraglutide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide injection is indicated to lower the risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes and established cardiovascular disease.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
SAXENDA is indicated (with diet and exercise) for long-term weight management in adults and in pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity, and in adults with overweight plus a comorbidity.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Victoza was authorised across the EU on 30 June 2009.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
In adults with type 2 diabetes and established cardiovascular disease, VICTOZA is used to reduce the risk of major cardiovascular events.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
On 21 May 2026, the CHMP recommended granting marketing authorisation for Liraglutide Stada.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide is used to lower the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide Injection is used with diet and exercise to improve blood sugar control in adults and children age 10 years and older with type 2 diabetes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
EMA concluded Saxenda’s benefits outweigh its risks and it can be authorised in the EU.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In adults with type 2 diabetes and established heart disease, liraglutide is indicated to lower the risk of major cardiovascular events.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide injection is indicated with diet and exercise to reduce excess body weight and help maintain long-term weight reduction in certain adults and in pediatric patients aged 12 years and older who meet the listed criteria.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
VICTOZA (liraglutide) is indicated to improve glycemic control in people aged 10 years and older with type 2 diabetes, alongside diet and exercise.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Administration
Product-specific route, timing, formulation, and use instructions—not universal dosing advice.
Inject liraglutide under the skin once daily, any time of day, with or without meals.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Inject VICTOZA under the skin once daily, any time of day, with or without meals.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Inject liraglutide under the skin once daily, any time of day, with or without meals, in the abdomen, thigh, or upper arm.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Victoza is a 6 mg/ml pre-filled pen injection taken once daily under the skin in the abdomen, thigh, or upper arm.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Inject liraglutide under the skin once daily, at any time of day, with or without meals.
4 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 4 source records.
Inject SAXENDA under the skin once daily (any time, with or without meals) in the abdomen, thigh, or upper arm.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Inject liraglutide under the skin once daily, any time of day, with or without meals.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Inject liraglutide under the skin once daily, any time of day, with or without meals, in the abdomen, thigh, or upper arm.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Inject SAXENDA under the skin once daily, any time of day, regardless of meals.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
If you use insulin with liraglutide injection, give them as separate injections and do not mix them.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Saxenda is injected under the skin once per day using a pre-filled pen (thigh, upper arm, or belly).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
SAXENDA is injected under the skin once daily, any time of day, with or without meals.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Stop Saxenda if weight loss after 12 weeks at the maximum (or maximum tolerated) dose is under 4% in adolescents/children (from 6 years) or under 5% in adults.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If you miss liraglutide for more than 3 days, restart at 0.6 mg once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If you miss liraglutide for more than 3 days, restart at 0.6 mg daily and re-titrate.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Inject liraglutide under the skin once daily, any time of day, with or without meals, in the abdomen, thigh, or upper arm.
6 cited sources · 4 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
6 cited passages across 6 source records.
Inject liraglutide injection under the skin once daily, at any time of day, with or without regard to meals.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Victoza is injected under the skin once daily (abdomen, thigh, or upper arm), independent of meals, preferably at the same time each day.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Inject liraglutide injection under the skin once a day, any time of day, with or without meals.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If you miss liraglutide for more than 3 days, restart at 0.6 mg once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If using insulin too, inject liraglutide separately and never mix them; they can be in the same general area but not right next to each other.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
You can inject liraglutide under the skin in the abdomen, thigh, or upper arm, and you don’t need to change the dose when switching sites or timing.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Inject liraglutide under the skin once daily, any time of day, with or without meals, in the abdomen, thigh, or upper arm.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Saxenda is injected once daily under the skin using a pre-filled pen (thigh, upper arm, or belly).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Inject liraglutide under the skin once a day, any time of day, with or without meals.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
You can inject liraglutide under the skin in the abdomen, thigh, or upper arm.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Inject liraglutide under the skin once daily (any time of day), in the abdomen, thigh, or upper arm; meal timing does not matter.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Dose records
Product- and indication-specific dose statements preserved separately to prevent unsafe generalization.
It comes as a 6 mg/mL injection in a 3 mL prefilled pen that can deliver 0.6, 1.2, 1.8, 2.4, or 3 mg doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adults start liraglutide at 0.6 mg under the skin once daily for 1 week, but that starting dose does not control blood sugar in adults.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After 1 week at 0.6 mg daily, adults increase to 1.2 mg under the skin once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Start at 0.6 mg daily for week 1, then increase weekly to reach 3 mg daily from week 5 onward.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In adults, start liraglutide 0.6 mg daily for 1 week, then increase to 1.2 mg daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Start at 0.6 mg daily for 1 week, then increase weekly to 3 mg daily by week 5.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adults: start with 0.6 mg under the skin once daily for one week.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
SAXENDA is a 6 mg/mL solution in a 3 mL prefilled pen that can deliver 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If needed in adults, increase liraglutide to 1.8 mg daily after at least 1 week on 1.2 mg daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For adults, start at 0.6 mg once daily for 1 week, then 1.2 mg once daily; if needed, increase to 1.8 mg once daily after at least 1 week on 1.2 mg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After 1 week at 0.6 mg daily, adults increase liraglutide to 1.2 mg daily (under the skin).
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Adults: target dose is 3 mg daily; stop SAXENDA if 3 mg is not tolerated.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Pediatrics: start 0.6 mg daily; after at least 1 week, may increase to 1.2 mg daily if needed; if needed, increase to 1.8 mg daily after at least 1 week on 1.2 mg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adults: the recommended dose is 3 mg daily; lower doses are only for titration.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 2 source records.
If it has been more than 3 days since the last dose, restart at 0.6 mg once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adults should use 3 mg daily; lower doses are only for titration.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
Adults usually start at 0.6 mg under the skin once daily for 1 week, then 1.2 mg once daily; if needed, increase to 1.8 mg once daily after at least 1 week on 1.2 mg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adults start liraglutide injection at 0.6 mg under the skin once daily for 1 week.
4 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 4 source records.
Victoza starts at 0.6 mg, increases to 1.2 mg after at least one week, and may increase to 1.8 mg one week later in some patients.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For adults, the maximum recommended dose is 1.8 mg under the skin once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adults start liraglutide injection at 0.6 mg under the skin once daily for 1 week.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adults: the recommended dose is 3 mg once daily; lower doses are only for dose-building (titration).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adults: SAXENDA is recommended at 3 mg once daily; lower doses are only for dose titration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For children ages 10 and up, start at 0.6 mg once daily and, if needed, increase by 0.6 mg steps no more often than weekly, up to 1.8 mg once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Start SAXENDA at 0.6 mg daily for one week, then increase weekly to 3 mg daily by Week 5 and onward.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For children aged 10 years and older, the maximum liraglutide injection dose is 1.8 mg under the skin once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Start at 0.6 mg daily for 1 week, then increase weekly to reach 3 mg daily from week 5 onward.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide comes as 18 mg/3 mL (6 mg/mL) solution in a prefilled pen delivering 0.6 mg, 1.2 mg, or 1.8 mg doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If adults need more blood sugar control, liraglutide can be increased up to 1.8 mg once daily after at least 1 week on 1.2 mg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adults: start 0.6 mg daily for 1 week, then 1.2 mg daily; if needed, increase to 1.8 mg daily after at least 1 week on 1.2 mg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For children ages 10+ years, start 0.6 mg under the skin once daily; if needed, increase by 0.6 mg steps after at least 1 week on the current dose, up to 1.8 mg once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If you miss liraglutide for more than 3 days, restart at 0.6 mg once daily to reduce GI side effects when restarting.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Start at 0.6 mg daily for 1 week, then increase weekly to 1.2 mg, 1.8 mg, 2.4 mg, and 3 mg from week 5 onward.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adults are escalated weekly from 0.6 mg daily to 3 mg daily by week 5 and onward; the recommended adult dosage is 3 mg daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The dose is slowly increased over 4 weeks.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 1 source record.
Studied populations
Who was represented in a study, label, or registry record.
Liraglutide STADA is intended to treat insufficiently controlled type 2 diabetes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Victoza is used with diet and exercise for adults and children aged 10 years and older with type 2 diabetes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide STADA is indicated for adults, adolescents, and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
No liraglutide dose adjustment is recommended for renal impairment.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Identity
Ingredient, molecule, and product identity statements.
Liraglutide is a GLP-1 receptor agonist in this study.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The included studies looked at GLP-1 RA exposure and included liraglutide among the drugs evaluated.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide was one of the GLP-1 receptor agonists evaluated in randomized trials in Parkinson’s disease.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study counted liraglutide prescriptions as GLP-1 therapy exposure.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide was one of the GLP-1 receptor agonists studied.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide was treated as a GLP-1 receptor agonist in this study.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is a GLP-1 analogue.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is a GLP-1 receptor agonist obesity medication.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide injection contains liraglutide, a human GLP-1 analog that works as a GLP-1 receptor agonist.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
Liraglutide is a lipidated GLP-1 receptor agonist.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Victoza’s active substance is liraglutide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This study included liraglutide as one of the GLP-1 receptor agonist medications examined.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide Injection contains liraglutide, an analog of human GLP-1 that acts as a GLP-1 receptor agonist.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide is a GLP-1 analogue.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is a GLP-1 receptor agonist.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide injection contains liraglutide, a GLP-1 analog that acts as a GLP-1 receptor agonist.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide is listed as a protein.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is a GLP-1 receptor agonist.
2 cited sources · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records. 2 publication group(s) lack a resolved study identity.
Liraglutide injection contains liraglutide, an analog of human GLP-1, and it acts as a GLP-1 receptor agonist.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide is a human GLP-1 analog that works as a GLP-1 receptor agonist.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
SAXENDA contains liraglutide, a human GLP-1 analog that works as a GLP-1 receptor agonist.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Saxenda’s active substance is liraglutide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide is a GLP-1 receptor agonist evaluated for weight management efficacy and safety.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is described as a GLP-1 analog.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide Injection contains liraglutide, a GLP-1 analog that acts as a GLP-1 receptor agonist.
2 cited sources · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Liraglutide is an acylated GLP-1 receptor agonist that is 97% homologous to human GLP-1(7-37).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide STADA’s active substance is liraglutide, a GLP-1 analogue (ATC code: A10BJ02).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide is a GLP-1 receptor agonist (in this OSA pharmacotherapy review).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is a GLP-1 receptor agonist used as an anti-obesity medication.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is a GLP-1 analogue.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is a glucagon-like peptide 1 analogue.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide is a long-acting GLP-1 receptor agonist.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide’s molecular formula is C172H265N43O51.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is an analog that has 97% homology to human GLP-1.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This review searched for "liraglutide" and included studies from 2014 to 2025.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Some active duty service members in this study started liraglutide (Saxenda).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
SAXENDA contains liraglutide, a GLP-1 analog that acts as a GLP-1 receptor agonist.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
VICTOZA contains liraglutide, a human GLP-1 analog that acts as a GLP-1 receptor agonist.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide is a GLP-1 receptor agonist used to manage type 2 diabetes and obesity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide’s molecular weight is 3751.26.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide Injection comes as a clear, colorless solution (18 mg/3 mL; 6 mg/mL) in a prefilled single-patient pen that can deliver 0.6 mg, 1.2 mg, or 1.8 mg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide Injection is a clear, colorless solution (18 mg/3 mL; 6 mg/mL) in a single-patient-use prefilled pen that can deliver 0.6 mg, 1.2 mg, or 1.8 mg doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide is a GLP-1 receptor agonist.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This analysis evaluated liraglutide for weight-management efficacy and safety.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Additional research & classification gaps
39 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.
Inspect contextual research (39)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
With liraglutide, 23.65% achieved ≥ 5% weight reduction and 7.05% achieved ≥ 10%, versus 68.15% and 32.59% with MCLOW (p< 0.001; p-value < 0.001).
Research context only—not evidence of a treatment effect.
- pubmed-42500463
and had a higher proportion achieved weight reductions of ≥ 5% and ≥ 10% (68.15% vs. 23.65%,p< 0.001 and 32.59% vs. 7.05%, p-value < 0.001, respectively).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A semaglutide-based classifier separated liraglutide from placebo (AUC = 0.82; sensitivity 0.89; specificity 0.60).
Research context only—not evidence of a treatment effect.
- Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.
A semaglutide-based classifier distinguished liraglutide from placebo (AUC = 0.82; sensitivity 0.89; specificity 0.60).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In FAERS, liraglutide had higher reporting for cholelithiasis than semaglutide (PRR 1.21).
Research context only—not evidence of a treatment effect.
- Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis.
Exenatide, liraglutide, and tirzepatide showed higher reporting for cholecystitis (PRR 1.12, 1.07, and 1.05) and cholelithiasis (PRR 1.33, 1.21, and 1.15).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The results were compared against a 30-protein semaglutide STEP 1/2 signature.
Research context only—not evidence of a treatment effect.
- Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.
Results were benchmarked against the 30-protein semaglutide STEP 1/2 signature.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In FAERS, liraglutide had higher reporting for cholecystitis than semaglutide (PRR 1.07).
Research context only—not evidence of a treatment effect.
- Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis.
Exenatide, liraglutide, and tirzepatide showed higher reporting for cholecystitis (PRR 1.12, 1.07, and 1.05)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In Croatia, semaglutide was the most used and most costly GLP-1 receptor agonist, followed by dulaglutide and liraglutide.
Research context only—not evidence of a treatment effect.
- Trends in glucagon-like peptide-1 receptor agonist utilization and expenditure in Croatia.
Semaglutide emerged as the dominant agent according to both utilization and cost, followed by dulaglutide and liraglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Loading and contribution line plots were used to identify the spectral features contributing most to variance.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
The application of principal component analysis (PCA) enabled the identification of clustering patterns and classification of samples under different stress conditions, while the analysis of loading and contribution line plots allowed recognition of the main spectral features contributing most to the variance.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Once-daily subcutaneous liraglutide reduced body weight versus control (standardized mean difference -0.945; 95% CI - 1.784 to -0.106).
Research context only—not evidence of a treatment effect.
- Glucagon-like peptide-1 receptor agonists for weight management in mental illness: a network meta-analysis.
S-LIR(QD) and S-SEM(QW) were significantly associated with reduced body weight compared with control, with standardized mean differences (95% confidence intervals) of -0.945 ( - 1.784 to -0.106) and -2.101 ( - 2.978 to -1.224), respectively.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide significantly changed 124 proteins (57 FDR < 0.05).
Research context only—not evidence of a treatment effect.
- Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.
Liraglutide significantly modulated 124 proteins (57 FDR < 0.05)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 100% coverage (broad criterion), the annual budget for liraglutide was S/142.95 billion.
Research context only—not evidence of a treatment effect.
- pubmed-42565180
At 100% coverage, broad-criterion annual budgets were S/142.95 billion for liraglutide
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In FAERS, liraglutide had a PRR of 0.30 (95% CI, 0.26 to 0.35) for diabetic foot reports.
Research context only—not evidence of a treatment effect.
- Assessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian Randomization.
This trend was consistently observed across individual GLP-1RA molecules, including semaglutide (PRR, 0.45; 95% CI, 0.39 to 0.51), dulaglutide (PRR, 0.49; 95% CI, 0.45 to 0.54), and liraglutide (PRR, 0.30; 95% CI, 0.26 to 0.35).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
With liraglutide, some pancreatic enzyme proteins went up (PNLIP, CTRB1/2, PRSS2).
Research context only—not evidence of a treatment effect.
- Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.
Upregulated proteins included pancreatic enzymes (PNLIP, CTRB1/2, PRSS2)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is used to induce weight loss.
Research context only—not evidence of a treatment effect.
- Effects of liraglutide on gut bacterial community dynamics.
is used to induce weight loss.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this real-world study, semaglutide users had lower incident diabetes risk than liraglutide users.
Research context only—not evidence of a treatment effect.
- Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.
In this real-world study, semaglutide users had lower risk of incident diabetes compared with liraglutide users.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Over 1-year mean follow-up, semaglutide users had lower diabetes risk than liraglutide users (HR: 0.88; 95% CI: 0.78, 0.99).
Research context only—not evidence of a treatment effect.
- Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.
Over 1-year mean follow-up, we observed 1104 diabetes events and 57 CVD events. After regression adjustment, semaglutide users had 12% lower risk of diabetes (hazard ratio [HR]: 0.88; 95% CI: 0.78, 0.99).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In an E. coli SUMO–liraglutide-derived peptide system, 3'-UTR hairpins increased cellular fusion-protein content by about 3-fold vs control (p < 0.001, n = 6).
Research context only—not evidence of a treatment effect.
- Engineering 3'-UTR hairpin structures to modulate mRNA stability and recombinant protein production in Escherichia coli.
In the SUMO-liraglutide-derived peptide system, mRNA stabilization was also pronounced, and the increase in specific cellular fusion-protein content reached approximately 3-fold (p < 0.001, n = 6).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In eight reviews on bone and fracture outcomes, liraglutide improved bone formation markers.
Research context only—not evidence of a treatment effect.
- Glucagon-Like Peptide-1 Receptor Agonists in Orthopedics: A Scoping Review of Emerging Applications.
Eight reviews assessed bone and fracture outcomes, showing that liraglutide reduced fracture risk and improved bone formation markers, while exenatide had mixed effects.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Early weight change (often checked within 12-16 weeks) is described as the most clinically actionable predictor of longer-term outcomes.
Research context only—not evidence of a treatment effect.
- Phenotypic and genomic frameworks for precision pharmacotherapy in obesity: a narrative review.
Early on-treatment weight change, usually assessed within 12-16 weeks and in some liraglutide studies as early as 1 month, is the most clinically actionable predictor of longer-term outcomes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
With agitation stress, liraglutide aggregated extensively and its structure changed in PS80 and PX188, and aggregation was faster with PS80.
Research context only—not evidence of a treatment effect.
- Impact of surfactants on the stability of therapeutic peptides under interfacial stress.
For liraglutide, which forms dynamic oligomers that are not intrinsically stable under agitation stress, SEC and CD reveal extensive aggregation and structural rearrangement in the presence of both PS80 and PX188, with PS80 driving more rapid aggregation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Conditioned medium from liraglutide-pretreated peritoneal macrophages reduced pyroptosis-related proteins in H9c2 cells.
Research context only—not evidence of a treatment effect.
- pubmed-42242503
Conditioned medium (CM) from Lira-pretreated peritoneal macrophages (PMs) inhibited the expression of pyroptosis-related proteins in H9c2 cells.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
PCA was used to find clustering patterns and classify samples under different stress conditions.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
The application of principal component analysis (PCA) enabled the identification of clustering patterns and classification of samples under different stress conditions, while the analysis of loading and contribution line plots allowed recognition of the main spectral features contributing most to the variance.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In FAERS pharmacovigilance data, liraglutide had an inverse signal with IBD reports (ROR 0.419, 95% CI 0.319-0.552).
Research context only—not evidence of a treatment effect.
- Prioritizing Antidiabetic Drugs for Inflammatory Bowel Disease Through Inverse Signal Detection: A FAERS Pharmacovigilance Study.
Within this broader pool, ten antidiabetic agents which demonstrated meaningful inverse signal strength were selected for in-depth analysis: dulaglutide (ROR 0.181, 95% CI 0.136-0.242), insulin lispro (ROR 0.206, 95% CI 0.161-0.263), insulin glargine (ROR 0.246, 95% CI 0.205-0.295), insulin (ROR 0.340, 95% CI 0.295-0.390), insulin aspart (ROR 0.349, 95% CI 0.267-0.455), empagliflozin (ROR 0.400, 95% CI 0.311-0.514), liraglutide (ROR 0.419, 95% CI 0.319-0.552), metformin (ROR 0.446, 95% CI 0.407-0.489), sitagliptin (ROR 0.460, 95% CI 0.376-0.563), and semaglutide (ROR 0.622, 95% CI 0.507-0.764).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Medium from liraglutide-pretreated peritoneal macrophages reduced pyroptosis-related proteins in H9c2 cells.
Research context only—not evidence of a treatment effect.
- pubmed-42242503
Conditioned medium (CM) from Lira-pretreated peritoneal macrophages (PMs) inhibited the expression of pyroptosis-related proteins in H9c2 cells.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Some liraglutide studies assess early weight change as early as 1 month.
Research context only—not evidence of a treatment effect.
- Phenotypic and genomic frameworks for precision pharmacotherapy in obesity: a narrative review.
Early on-treatment weight change, usually assessed within 12-16 weeks and in some liraglutide studies as early as 1 month, is the most clinically actionable predictor of longer-term outcomes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Even with short incubation and a dry film method, the study detected clear changes tied to early and advanced degradation in the liraglutide peptide formulations.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
Despite the relatively short incubation times and using a dry film approach which may introduce conformational changes, clear changes associated with early and advanced phases of degradation were detected.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The system restored JC-1 mitochondrial membrane potential to 71.5% of control.
Research context only—not evidence of a treatment effect.
- Oral Janus nanomotor covalent conjugation rapeseed protein-derived DPP-IV inhibitory peptide and liraglutide: A self-propelled targeted delivery system for promoting insulin secretion and glucose-lowering.
and restored mitochondrial membrane potential (JC-1 red/green fluorescence ratio) to 71.5% of the control level.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After stopping liraglutide 3.0 mg, pooled average weight regain was 4.83% (k = 4; 95% CI: 3.87-5.79) from end-of-treatment to follow-up.
Research context only—not evidence of a treatment effect.
- Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis.
Subgroup analysis by drug class yielded: semaglutide 2.4 mg, 7.19% (k = 6; 95% CI: 6.42-7.96); liraglutide 3.0 mg, 4.83% (k = 4; 95% CI: 3.87-5.79); and tirzepatide, 13.04% (k = 3; 95% CI: 11.87-14.21).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the LEAD program, liraglutide (alone or with other diabetes medicines) controlled hyperglycemia and reduced A1C by up to 1.6%.
Research context only—not evidence of a treatment effect.
- Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
The Liraglutide Effect and Action in Diabetes (LEAD) program demonstrated that liraglutide, when used alone or in combination with other antidiabetic medications, effectively controls hyperglycemia (glycosylated hemoglobin [A1C] reductions up to 1.6%)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The system scavenged intracellular ROS at an 89.74% rate.
Research context only—not evidence of a treatment effect.
- Oral Janus nanomotor covalent conjugation rapeseed protein-derived DPP-IV inhibitory peptide and liraglutide: A self-propelled targeted delivery system for promoting insulin secretion and glucose-lowering.
The system effectively scavenged intracellular reactive oxygen species (ROS) with an 89.74% scavenging rate
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 receptor agonists such as liraglutide cause substantial weight loss (mostly fat), and 20-30% of the weight lost is lean mass.
Research context only—not evidence of a treatment effect.
- Incretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications-A Narrative Review.
GLP-1 RAs (semaglutide, liraglutide, tirzepatide, exenatide) induce substantial weight loss (predominantly fat mass) but also reduce lean mass by 20-30% of total weight loss.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In eight reviews on bone and fracture outcomes, liraglutide reduced fracture risk.
Research context only—not evidence of a treatment effect.
- Glucagon-Like Peptide-1 Receptor Agonists in Orthopedics: A Scoping Review of Emerging Applications.
Eight reviews assessed bone and fracture outcomes, showing that liraglutide reduced fracture risk and improved bone formation markers, while exenatide had mixed effects.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide strongly lowered myostatin (MSTN) (log₂ fold change -0.41; p = 1.7 × 10-6).
Research context only—not evidence of a treatment effect.
- Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.
Myostatin (MSTN) was strongly suppressed (log₂ fold change -0.41; p = 1.7 × 10-6)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide was developed for obesity and diabetes care.
Research context only—not evidence of a treatment effect.
- Incretin-Based Therapies in Obesity-Related Obstructive Sleep Apnea: A Narrative Review of Evidence Tiers and Mechanistic Plausibility.
Newer medicines such as liraglutide and tirzepatide were developed for obesity and diabetes care
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide’s ChEMBL ID is CHEMBL4084119.
Research context only—not evidence of a treatment effect.
- LIRAGLUTIDE
ChEMBL ID: CHEMBL4084119
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The preferred name is LIRAGLUTIDE.
Research context only—not evidence of a treatment effect.
- LIRAGLUTIDE
Preferred name: LIRAGLUTIDE
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Plasma and serum were tested with SomaScan v4.1 to measure 6249 proteins.
Research context only—not evidence of a treatment effect.
- Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.
Plasma and serum samples underwent SomaScan v4.1 profiling of 6249 proteins.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide’s main mechanism changes with metabolic state: brain (tanycyte-mediated) in healthy conditions, direct islet effects in glucose intolerance, and insulin-independent mechanisms across metabolic states.
Research context only—not evidence of a treatment effect.
- pubmed-42350670
Liraglutide operates through complementary, metabolic state-dependent pathways: tanycyte-mediated brain actions predominate in healthy conditions, direct islet effects emerge during glucose intolerance and insulin-independent mechanisms maintain efficacy across metabolic states.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The findings state that targeting both iron overload and antioxidant signaling gave stronger protection against doxorubicin heart injury (in this model using liraglutide plus deferoxamine).
Research context only—not evidence of a treatment effect.
- Synergistic cardioprotection by liraglutide and deferoxamine against doxorubicin-induced cardiotoxicity via modulation of ACSL-4/Nrf-2/GPX-4 signaling.
These findings demonstrate that simultaneous targeting of iron overload and antioxidant signaling confers enhanced cardioprotection against Dox-induced injury.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
They collected 7.1 million 16S rRNA gene sequences using Illumina paired-end sequencing.
Research context only—not evidence of a treatment effect.
- Effects of liraglutide on gut bacterial community dynamics.
For bacterial community analysis, 7.1 million 16S rRNA gene sequences were retrieved using Illumina paired-end sequencing.
Safety + tolerability
Risks, organized for scanning.
Labels warn about thyroid C-cell tumors observed in rodents; human relevance is unknown. [1]Regulatory labelVictoza prescribing informationDailyMed label for liraglutide marketed as Victoza.
Contraindications
- Medullary thyroid carcinoma history
- MEN 2
- Serious hypersensitivity
Common effects
- Nausea
- Diarrhea
- Vomiting
Serious risks
- Pancreatitis
- Gallbladder disease
- Hypoglycemia with selected therapies
Structured from current product labeling [1]Regulatory labelVictoza prescribing informationDailyMed label for liraglutide marketed as Victoza.
Products + regulatory context
Same ingredient. Different records.
| Product | Form | Profile scope | Record |
|---|---|---|---|
| Victoza | Daily subcutaneous injection | Type 2 diabetes and specified cardiovascular risk reduction. | [1]Regulatory labelVictoza prescribing informationDailyMed label for liraglutide marketed as Victoza. |
| Saxenda | Daily subcutaneous injection | Chronic weight management in specified populations. | [16]Published evidence snapshotThese highlights do not include all the information needed to use SAXENDA®safely and effectively. See full prescribing information for SAXENDA.SAXENDA (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010dailymed · T1 |
Do not infer dosing, interchangeability, or an approved use from the ingredient name alone. Open the current label for the exact product and presentation.
Administration, interactions + monitoring
The practical clinical context.
- Administration boundary
- Once-daily subcutaneous injection with product-specific titration. [1]Regulatory labelVictoza prescribing informationDailyMed label for liraglutide marketed as Victoza.
Research status + gaps
What still needs better answers.
Some extracted findings are not shown because they did not pass Peplexicon's automated evidence checks.
How Peplexicon reads evidence
- Authority
- What kind of source is making the statement?
- Independence
- Do multiple citations represent separate studies—or the same evidence repeated?
- Directness
- Does the population, product, dose, outcome, and time horizon match the claim?
- Consistency
- Do credible sources support, qualify, or contradict one another?
References + discovery
Open the records yourself.
- 1Regulatory labelVictoza prescribing informationOpen ↗
DailyMed label for liraglutide marketed as Victoza.
- 2Literature indexEvery PubMed result for liraglutideOpen ↗
Live National Library of Medicine literature search; results are not pre-screened or deduplicated.
- 3Trial registryEvery registered study for liraglutideOpen ↗
Live ClinicalTrials.gov search, including completed, active, and historical records.